Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2019
Principal Executive Offices: Vancouver, B.C.
Trading Symbol: ACHV (NASDAQ Capital Market)
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the issuance of a press release (Exhibit 99.1) announcing clinical trial results. Specifically, the Company reported statistically significant improvement in quit rates for its simplified cytisinicline dosing schedule in Phase 2b of the ORCA-1 dose-selection trial.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the positive clinical outcome of the ORCA-1 trial, highlighting the efficacy of the simplified dosing schedule.
Guidance and Risks: The filing text does not provide updated financial guidance, specific risk factors, or details on contingencies beyond the clinical trial update.
Investor Verification Checklist
- Verify the full details of the Phase 2b ORCA-1 trial results in the attached press release (Exhibit 99.1).
- Confirm the specific statistical significance and quit rate percentages reported in the clinical data.
- Review subsequent filings for any impact of these results on the Company's regulatory strategy or development timeline.
- Check the Company's most recent 10-Q or 10-K for current financial health, as this 8-K contains no financial data.